COMPARATIVE EFFICACY AND SAFETY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA USING A MATCHING-ADJUSTED INDIRECT COMPARISON

被引：0
|
作者：
Leleu, X. [1 ]
Delea, T. [2 ]
Guyot, P. [3 ]
Moynahan, A. [2 ]
Singh, E. [4 ]
Tekle, C. [4 ]
Lin, P. [4 ]
机构：
[1] Univ Poitiers Hosp, Poitiers, France
[2] Policy Anal Inc, Brookline, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC34
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [31] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Trudel, Suzanne
    Davis, Randy
    Lewis, Nicole M.
    Bakshi, Kalpana K.
    Chopra, Bikramjit
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Eliason, Laurie
    Kremer, Brandon E.
    Stowell, Delia
    Gupta, Ira
    Wu, Frank S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
  • [32] Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup analysis of ICARIA-MM study
    Ikeda, T.
    Sunami, K.
    Huang, S-Y.
    Wang, M-C.
    Koh, Y. I.
    Min, C. G.
    Yeh, S-P.
    Matsumoto, M.
    Uchiyama, M.
    Iyama, S.
    Shimazaki, C.
    Lee, J. H.
    Kim, K. H.
    Kaneko, H.
    Kim, J. S.
    Lin, T-L.
    Campana, F.
    Tada, K.
    Iida, S.
    Suzuki, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey S. Y.
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth C.
    BLOOD, 2022, 140
  • [34] Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
    Schjesvold, Fredrik
    Richardson, Paul G.
    Facon, Thierry
    Alegre, Adrian
    Spencer, Andrew
    Jurczyszyn, Artur
    Sunami, Kazutaka
    Frenzel, Laurent
    Min, Chang-Ki
    Guillonneau, Sophie
    Lin, Peggy L.
    Le-Guennec, Solenn
    Campana, Frank
    van de Velde, Helgi
    Bensfia, Samira
    Bringhen, Sara
    HAEMATOLOGICA, 2021, 106 (04) : 1182 - 1187
  • [35] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study
    Decaux, Olivier
    Fontan, Jean
    Perrot, Aurore
    Karlin, Lionel
    Touzeau, Cyrille
    Schulmann, Samantha
    Manier, Salomon
    Belhadj, Karim
    Trebouet, Adrien
    Zunic, Patricia
    Schiano De Colella, Jean-Marc
    Castel, Brice
    van de Wyngaert, Zoe
    Pica, Gian Matteo
    Tiab, Mourad
    Kuhnowski, Frederique
    Bouketouche, Malek
    Rigaudeau, Sophia
    Benramdane, Riad
    Tekle, Christina
    Lafore, Radhia
    Gaucher, Marianne
    Corre, Jill
    Leleu, Xavier
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (03) : 290 - 297
  • [36] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
    Richardson, Paul
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
  • [37] Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
    Schjesvold, Fredrik
    Bringhen, Sara
    G. Richardson, Paul
    Perrot, Aurore
    Leleu, Xavier
    Moreau, Philippe
    A. Dimopoulos, Meletios
    Hulin, Cyrille
    Tekle, Christina
    Foster, Meredith C.
    Poole, Elizabeth M.
    van de Velde, Helgi
    Facon, Thierry
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (11) : E423 - E427
  • [38] The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
    Shimazu, Yutaka
    Kanda, Junya
    Onda, Yoshiyuki
    Fuchida, Shin-ichi
    Ohta, Kensuke
    Shimura, Yuji
    Kosugi, Satoru
    Yamamura, Ryosuke
    Matsuda, Mitsuhiro
    Hanamoto, Hitoshi
    Adachi, Yoko
    Anzai, Naoyuki
    Hotta, Masaaki
    Fukushima, Kentaro
    Yagi, Hideo
    Yoshihara, Satoshi
    Tanaka, Yasuhiro
    Takakuwa, Teruhito
    Tanaka, Hirokazu
    Shibayama, Hirohiko
    Uoshima, Nobuhiko
    Hosen, Naoki
    Ito, Tomoki
    Shimazaki, Chihiro
    Matsumura, Itaru
    Kuroda, Junya
    Takaori-Kondo, Akifumi
    Hino, Masayuki
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
  • [39] An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma
    Piggin, Anna
    Prince, H. Miles
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 419 - 427
  • [40] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Ahmadi, Tahamtan
    Ukropec, Jon
    Kampfenkel, Tobias
    Schecter, Jordan
    Qiu, Yanping
    Amin, Himal
    Vermeulen, Jessica
    Carson, Robin
    Sonneveld, Pieter
    BLOOD, 2020, 136
12345